Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | GLI1 | P08151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417059 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1DPP4MEN1 | |
| SCHEMBL417060 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1DPP4MEN1 | |
| SCHEMBL9022161 | 0.82 | NOS2 (0.42) | NOS2NOS3NOS1DPP4MEN1 | |
| SCHEMBL27548535 | 0.78 | NOS2 (0.42) | NOS2NOS3NOS1DPP4MEN1 | |
| SCHEMBL3113842 | 0.77 | NOS2 (0.42) | NOS2NOS3NOS1DPP4MEN1 | |
| Cadaverine Tartrate SCHEMBL27475560 | 0.76 | MEN1 (0.42) | NOS2NOS3NOS1DPP4MEN1 | |
| SCHEMBL14443285 | 0.75 | NOS2 (0.43) | NOS2NOS3NOS1DPP4MEN1 | |
| SCHEMBL801077 | 0.75 | NOS2 (0.43) | NOS2NOS3NOS1DPP4MEN1 | |
| SCHEMBL800667 | 0.75 | NOS2 (0.43) | NOS2NOS3NOS1DPP4MEN1 | |
| Proline SCHEMBL1740645 | 0.74 | TP53 (0.42) | NOS2NOS3NOS1DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322998-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-18 | — | — | US | claimed |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-01-26 | — | — | US | claimed |
| US-20040116654-A1 | Heterogeneous foldamers containing alpha, beta, and/or gamma-amino acids | NATIONAL SCIENCE FOUNDATION | 2004-06-17 | — | — | US | claimed |
| US-10322998-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-8772450-B2 | Beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130023644-A1 | BETA-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-01-24 | — | — | US | disclosed |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-01-26 | — | — | US | disclosed |
| US-7858737-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20070123709-A1 | Beta-amino acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-31 | — | — | US | disclosed |
| US-20040116654-A1 | Heterogeneous foldamers containing alpha, beta, and/or gamma-amino acids | NATIONAL SCIENCE FOUNDATION | 2004-06-17 | — | — | US | disclosed |
| WO-2004018644-A2 | HETEROGENEOUS FOLDAMERS CONTAINING α, β, AND/OR Ϝ-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-6683154-B1 | UNNATURAL CATIONIC OLIGOMERS THAT HAVE NO KNOWN NATURAL COUNTERPART AND THAT DISPLAY ANTIBIOTIC ACTIVITY COMPARABLE TO THAT OF MAGAININ DERIVATIVE AGAINST AT LEAST FOUR DIFFERENT BACTERIAL SPECIES, YET EXHIBIT LOWER HEMOLYTIC ACTIVITY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-01-27 | — | — | US | disclosed |
| US-6613876-B1 | Covalently linking subunit of given formula to a plurality of separable solid substrates; deprotecting; used for generating combinatorial libraries | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-09-02 | — | — | US | disclosed |
| WO-2003008439-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING β-AMINO ACID OLIGOMERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20020037997-A1 | Beta-amino acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-03-28 | — | — | US | disclosed |
| US-6060585-A | β-polypeptide foldamers of well-defined secondary structure | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322998-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | DNPEP, PRKCSH, BCAT1 | NOS2 4587/4885NOS3 4274/4885NOS1 4318/4885 |
| US-20070123709-A1 | Beta-amino acids | BCAT1, MARCKS, YWHAZ | NOS2 2544/4885NOS3 2677/4885NOS1 3011/4885 |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | DNPEP, PRKCSH, YWHAZ | NOS2 4592/4885NOS3 4374/4885NOS1 4383/4885 |
| US-20020037997-A1 | Beta-amino acids | BCAT1, BCAT2, MARCKS | NOS2 3440/4885NOS3 3187/4885NOS1 3895/4885 |
| US-20130023644-A1 | BETA-AMINO ACIDS | BCAT1, MARCKS, YWHAZ | NOS2 2544/4885NOS3 2677/4885NOS1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.